Want to see ARVN full AI Analyst Report?
Top Page
Arvinas Holding Company
(NASDAQ:ARVN)
Select Model
Select Model
Rating:62Neutral
Price Target:
$8.00
▼(-16.67% Downside)
Action:Reiterated
Date:08/05/26
ARVN scores mid-range primarily due to strong balance-sheet flexibility and a generally positive earnings-call outlook with meaningful milestones and clear upcoming catalysts. The score is held back by sustained heavy cash burn (weak operating/free cash flow) and limited valuation support (negative P/E, no dividend), while technicals are only moderately positive given weakness versus longer-term moving averages.
Positive Factors
PROTAC leadership and validation
FDA approval of the first PROTAC degrader validates Arvinas’s core targeted-protein-degradation platform and provides external commercial support through the Rigel out-license. This strengthens the company’s credibility with partners while creating potential future royalty or commercial economics.
Negative Factors
Persistent cash burn
Deeply negative operating and free cash flow show that Arvinas remains dependent on its balance sheet and future collaboration economics to fund operations. Continued development spending can reduce liquidity before products generate recurring revenue, increasing execution and financing exposure.
Read all positive and negative factors
Positive Factors
Negative Factors
PROTAC leadership and validation
FDA approval of the first PROTAC degrader validates Arvinas’s core targeted-protein-degradation platform and provides external commercial support through the Rigel out-license. This strengthens the company’s credibility with partners while creating potential future royalty or commercial economics.
Read all positive factors
Arvinas Holding Company (ARVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$490.40M
Dividend YieldN/A
Average Volume (3M)750.47K
Price to Earnings (P/E)40.7
Beta (1Y)1.36
Revenue Growth-15.05%
EPS GrowthN/A
CountryUS
Employees246
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.19
Shares Outstanding65,386,190
10 Day Avg. Volume1,010,495
30 Day Avg. Volume750,466
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.77
Price to Sales (P/S)2.93
P/FCF Ratio-2.79
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.96Price Target Upside55.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$296.10M
Arvinas Holding Company Business Overview & Revenue Model
Company Description
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promisi...
How the Company Makes Money
As a clinical-stage biotechnology company, Arvinas has historically generated the majority of its revenue from collaboration arrangements rather than from product sales (it does not have broadly commercialized, marketed products). Key revenue stre...
Arvinas Holding Company Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 10, 2026
Earnings Call Sentiment Positive
The call emphasized major strategic and scientific milestones — notably the first PROTAC approval (VEPPANU), substantial one-time revenue recognition and continued advancement of multiple clinical and preclinical programs with clear near-term data catalysts. Arvinas has strengthened focus on Phase I oncology and neurology assets, reported meaningful cost reductions and maintained a cash runway into H2 2028. Offsetting these positives are execution and timing challenges: ARV-393 enrollment was slowed by conservative starting doses (yielding mostly sub-efficacious cohort data in 2026), ARV-102 experienced regulatory delays pushing patient trials into 2027, cash declined ~17% YoY, and recent revenue was materially driven by one-time licensing and milestone events. Overall, the call leans positive because substantive strategic wins, upcoming clinical catalysts and a solid balance sheet (despite the cash decline) outweigh the program-specific delays and one-time accounting impacts.Positive Updates
First-Ever PROTAC Approval and Out-License
FDA approval of VEPPANU (first-ever PROTAC degrader) and out-license to Rigel Pharmaceuticals; generated a $50.0M Pfizer milestone and Rigel license revenue of $62.5M (of which $35.0M was received in the quarter).
Negative Updates
Decline in Cash Compared with Prior Year
Cash, cash equivalents and marketable securities fell to $567.9M from $685.4M at end of 2025, a decrease of $117.5M (~17.1%), reducing but still leaving runway into H2 2028.
Read all updates
Q2-2026 Updates
Positive
Negative
First-Ever PROTAC Approval and Out-License
FDA approval of VEPPANU (first-ever PROTAC degrader) and out-license to Rigel Pharmaceuticals; generated a $50.0M Pfizer milestone and Rigel license revenue of $62.5M (of which $35.0M was received in the quarter).
Read all positive updates
Company Guidance
Arvinas said it is well‑capitalized to advance key catalysts, reporting $567.9M in cash, cash equivalents and marketable securities at 2Q26 (versus $685.4M at end‑2025) and reiterating a cash runway into the second half of 2028; near‑term clinical and regulatory guidance includes initial ARV‑393 Phase I data by year‑end 2026 with more mature monotherapy (including DLBCL) and glofi combination data planned in 2027, ARV‑027 having completed single‑ascending doses and now in multiple‑dose cohorts with exposure, muscle AR degradation (target >50%) and initial safety data expected in H1‑2027 and patient dosing to follow (potential registrational path post‑Phase I), and ARV‑102 presenting additional ocular‑motor and CSF proteomics biomarker data at MDS in October 2026 while patient trials are now expected to start in 2027 after FDA questions and completion of chronic tox; 2Q26 financials and accounting actions: total revenue $249.7M, license revenue $62.5M ( $35M received in‑quarter ), $50M Pfizer milestone and $3.5M Pfizer research revenue, recognition of deferred revenue leading to $126.4M moved to the P&L, a $52.7M liability booked for VEPPANU runout (current $28.4M / long‑term $24.3M), cost of license revenue $9M (Yale payments), G&A $24M (vs $25.3M prior year), R&D $52.6M (vs $68.6M prior year), non‑GAAP R&D down $8.1M (‑14%) and non‑GAAP G&A up $0.3M (+2%), and the company expects to fund operations through upcoming data milestones.Arvinas Holding Company Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
80
Positive
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 316.70M | 262.60M | 263.40M | 78.50M | 131.40M | 53.60M |
| Gross Profit | 305.40M | 257.40M | 263.40M | 78.50M | 131.40M | 53.60M |
| EBITDA | 2.90M | -75.30M | -191.70M | -359.70M | -253.40M | -184.90M |
| Net Income | 9.30M | -80.80M | -198.90M | -367.30M | -282.50M | -191.00M |
Balance Sheet | ||||||
| Total Assets | 675.10M | 717.90M | 1.09B | 1.30B | 1.27B | 1.58B |
| Cash, Cash Equivalents and Short-Term Investments | 567.90M | 685.40M | 1.04B | 1.26B | 1.21B | 1.50B |
| Total Debt | 8.20M | 8.90M | 9.70M | 3.20M | 5.50M | 5.00M |
| Total Liabilities | 112.90M | 284.10M | 529.70M | 644.60M | 703.90M | 799.90M |
| Stockholders Equity | 562.20M | 433.80M | 561.70M | 660.00M | 564.90M | 781.70M |
Cash Flow | ||||||
| Free Cash Flow | -208.80M | -275.70M | -261.10M | -350.70M | -280.30M | 554.70M |
| Operating Cash Flow | -207.00M | -273.80M | -259.30M | -347.80M | -273.50M | 559.40M |
| Investing Cash Flow | 277.90M | 407.60M | 34.70M | 203.50M | 242.80M | -1.31B |
| Financing Cash Flow | -91.50M | -91.40M | 7.90M | 374.70M | 4.70M | 278.60M |
Arvinas Holding Company Technical Analysis
Negative
9.60
Price Trends
8.66
Negative
8.51
Negative
10.21
Negative
Market Momentum
-0.35
Positive
29.60
Positive
12.42
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARVN, the sentiment is Negative. The current price of 9.6 is above the 20-day moving average (MA) of 8.45, above the 50-day MA of 8.66, and below the 200-day MA of 10.21, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 29.60 is Positive, neither overbought nor oversold. The STOCH value of 12.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARVN.
Arvinas Holding Company Risk Analysis
Arvinas Holding Company disclosed 71 risk factors in its most recent earnings report. Arvinas Holding Company reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Arvinas Holding Company Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.51B | 7.45 | 2515.23% | ― | 92.92% | ― | |
62 Neutral | $490.40M | 40.71 | 1.91% | ― | -15.05% | ― | |
62 Neutral | $1.07B | 14.47 | 284.38% | ― | 948.35% | ― | |
56 Neutral | $1.23B | -6.00 | -41.49% | ― | ― | -63.70% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $747.23M | -4.08 | -48.22% | ― | ― | -10.16% | |
44 Neutral | $198.10M | -2.51 | -38.71% | ― | ― | 10.44% |
* Healthcare Sector Average
ARVN
Arvinas Holding Company
7.74
-1.40
-15.28%
ANAB
AnaptysBio
50.26
28.95
135.85%
MGTX
Meiragtx Holdings
11.00
2.73
33.01%
CMPX
Compass Therapeutics
1.04
-2.32
-69.05%
OLMA
Olema Pharmaceuticals
8.64
-2.40
-21.74%
BCAX
Bicara Therapeutics Inc.
18.61
2.00
12.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.